Guggenheim 3rd Annual Healthcare Innovation Conference - SPRUCE BIOSCIENCES INC

Explicit Guidance:

• Regulatory Timeline: Plans to submit a Biologics License Application (BLA) to the FDA in December (current year); aims for FDA acceptance in February (next year) and potential approval in the late summer/early autumn (August–September) timeframe of next year.
• Revenue/Cash Flow: Intends to monetize the Priority Review Voucher (PRV) immediately upon BLA acceptance/approval to fund U.S. commercialization; expects to pay total milestone payments to Biomarin ranging between $20 million and $30 million over the first two years of commercial net sales.
• Pricing Strategy: Targets a price point commensurate with disease severity, projecting a range between $1 million and $4 million per patient per year (avoiding the weight-based costs seen in competitor therapies like Fayuvi, which can reach $2.8M for adult weights).
• Manufacturing Timeline: Completion of the second Process Performance Qualification (PPQ) run for the drug product expected by end of current year; will submit analytical reports for Drug Substance (DS) and Drug Product (DP) prior to the mid-cycle FDA meeting.

Business-Segment Outlook:

• Product Launch & Distribution: Initiating a commercialization framework in Europe in Q4 of the current year via local distributors, partners, or a name-patient program; focusing U.S. sales efforts on 15 NORD-approved lysosomal storage disease centers of excellence (5 specific to MPS) and existing claims databases.
• Patient Identification: Identifies a potential US patient pool of approximately 450 diagnosed MPS3B patients (out of ~1,400 total MPS III diagnoses) currently accessible via claims analysis and center-of-excellence databases.
• Treatment Expansion: Anticipates treating patients beyond early childhood, including older children and young adults, aiming to halt disease progression even in advanced cases based on biomarker stability data.
• Data Release: Plans to present additional non-public biomarker data (including NFL, GM2, and GM3) at the World Meeting in February in San Diego.

Market and Competitive Outlook:

• Competitive Landscape: Positions tralcinase alpha as the only potential life-transforming therapy for MPS3B, distinct from weight-based gene therapies (e.g., Denali's compound) and the recently approved Fayuvi ($4M price point); expects strong demand given the "clamoring" by the patient community.
• Pricing Dynamics: Aims to balance high-value pricing for rare disease severity with patient access, differentiating via a fixed-dose, every-other-week administration model to avoid the high costs associated with weight-based scaling in adult patients.
• Market Share: Anticipates a concentrated patient base, leveraging a specialized Salesforce and Medical Science Liaison (MSL) team to tap into the existing 450-500 patient universe.

Macro / Industry Outlook:

• Regulatory Environment: Confirms strong alignment with FDA on the BLA framework and the requirement for a confirmatory trial (underway) at submission to avoid post-approval study delays; expects a clear approval pathway based on the "XERA" precedent (heparin sulfate as a reasonably likely surrogate endpoint).
• Global Regulatory Strategy: Acknowledges increasing difficulty in the European market, prompting a strategic pivot to revamp the European engagement (CHMP/PIP) starting in Q4, potentially utilizing name-patient programs for initial access.

Strategic Initiatives:

• BLA Submission: Finalizing a "tight story" for the December BLA submission, including two pre-BLA meetings held on CMC and clinical data.
• Clinical Trials: Active enrollment in a confirmatory registration trial (using Bayley's cognitive scoring) to ensure full approval under the Accelerated Approval pathway, alongside an expanded access program for pre-commercial patient access.
• Commercialization Financing: Strategic plan to use PRV monetization proceeds to self-fund U.S. commercialization efforts.
• Milestone Management: Structuring royalty and milestone payments to Biomarin as tiered, region-specific obligations totaling ~$130M over time, with $20–30M expected in the initial two-year window.

Risks and Headwinds to Outlook:

• Regulatory Uncertainty: While confidence is high, final FDA decision on the acceptance of heparin sulfate as an RLSE (Reasonably Likely to Substitute for Endpoints) remains a key review issue; potential for FDA debate on functional measures (cognitive scores) due to natural history baseline imbalances.
• Market Access/Reimbursement: Potential challenges in pricing accessibility for payers given the high price point of similar ultra-rare therapies ($1M–$4M range).
• Operational Execution: Reliance on completing the second PPQ run by year-end and operationalizing the confirmatory trial in time for BLA submission.
• Disease Heterogeneity: Variability in patient disease stages and decline speeds (addressed via propensity score matching and modeling) could impact clinical data interpretation.

Management Tone on the Future:

• Confidence Level: High confidence and optimism ("incredibly profound," "super strong," "very tight story") regarding the clinical data and regulatory pathway.
• Strategic Stance: Aggressive and proactive; management expresses certainty that the FDA is "compelled by the story" and expects approval without an Advisory Committee (ADCOM) meeting.
• Comparative View: Views the current package as meeting regulatory standards for a "proper package" and anticipates a full approval similar to the recent Fayuvi gene therapy approval.

Miscellaneous:

• Manufacturing Change: Drug product manufacturing site transitioned from Vetern Germany to Samsung Biologics in South Korea, requiring qualification via the second PPQ run.
• Natural History Study: Utilizes a proprietary, company-run natural history study (rather than external controls) to support clinical analysis and baseline comparisons.